PepGen(US:PEPG)2026-03-31 21:32Summary of PepGen Conference Call Company Overview - Company: PepGen - Study: Phase II FREEDOM2 study of PGN-EDODM1 Key Points Industry and Company Context - The conference call discusses the results from the FREEDOM2 study, focusing on the safety and efficacy of PGN-EDODM1 in treating myotonic dystrophy type 1 [1][2][4]. Core Findings - Safety Profile: At a dose of 5 mg/kg, PGN-EDODM1 demonstrated a promising safety profile with all adverse events classified as mild or moderate. No serious adverse events or treatment-related kidney issues were reported [4][11]. - Splicing Correction: The mean splicing correction in the treatment group was 7.3%, compared to 6.8% in the placebo group. Excluding an outlier, the mean splicing correction increased to 22.9% [5][12][13]. - Functional Outcomes: Improvements in hand myotonia were observed, with the video hand opening time (vHOT) improving by up to 4.1 seconds in the treatment group [13][14]. Recruitment and Future Data - Recruitment for the 10 mg/kg cohort is progressing well, with expectations to report clinical data in the second half of 2026 [5][16]. - The company has a cash runway extending into the second half of 2027, sufficient to support ongoing studies [16]. Additional Insights - Outlier Analysis: One patient in the treatment group exhibited a 70.8% worsening in splicing, which was not typical and is under investigation. The patient had significant drug levels, but the reason for the poor response remains unclear [12][17][21][48]. - Statistical Analysis: The study is not powered for statistically significant data but aims to explore safety and dose-finding up to 12.5 mg/kg [55]. - Safety at Higher Doses: Confidence in the safety profile for the upcoming 10 mg/kg cohort is high, with no cumulative toxicity observed in the 5 mg/kg cohort [28][31]. Regulatory and Market Considerations - The company is in discussions with the FDA regarding lifting a hold on the study, but no timeline can be provided at this moment [35]. - The potential for further improvements in splicing and functional outcomes is anticipated as dosing increases [22][49]. Conclusion - The results from the FREEDOM2 study indicate a favorable safety and efficacy profile for PGN-EDODM1, supporting continued development and higher dosing in future cohorts [14][58].